Pfizer secures option to acquire Vivet for up to $635.8m
Pfizer secures an exclusive option to acquire Vivet for up to $635.8m after collaborating with the biotech to develop an AAV gene therapy treatment.
Archives for March 20, 2019
WuXi Biologics becomes first Chinese EU approved CDMO
WuXi Biologics receives EMA GMP certification for the production of Trogarzo at its manufacturing facilities in Wuxi city and Shanghai, China.
Abzena tapped as CMC for Lipum’s biologic development project
Abzena and Lipum enter agreement for the development of biologics for juvenile idiopathic arthritis, using the former’s proprietary cell line and GMP resources.
Takeda’s plasma manufacturing facility approved by FDA
US FDA approves Takeda’s acquired plasma manufacturing facility in Georgia, US, for the production of flexbumin 25% solution.